COMPREHENSIVE CRITERIA FOR ASSESSING THERAPY-INDUCED TOXICITY

被引:208
作者
AJANI, JA
WELCH, SR
RABER, MN
FIELDS, WS
KRAKOFF, IH
机构
[1] Division of Medicine, University of Texas, M. D. Anderson Cancer Center at Houston
关键词
D O I
10.3109/07357909009017560
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Methods of assessing and reporting toxic reactions induced by therapy, particularly chemotherapy, need improvements. Accurate and reliable reporting of therapyinduced toxicity will be necessary for quality clinical research including drug development and for implementation of complex multìmodality treatments, currently, however, the extent and quality of reporting of toxic reactions vary widely. Whereas standard and widely accepted criteria have been established for assessing and reporting therapeutic response, no such criteria exist for toxicity. We have developed comprehensive criteria for assessing and reliably reporting toxic reactions. We have reduced the degree of subjectivity in assigning grades by using primarily objective methods. An attempt has been made to standardize the (morbidity impact) of each toxicity grade irrespective of the organ system involved. © 1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
引用
收藏
页码:147 / 159
页数:13
相关论文
共 28 条
[11]  
2-P
[12]   TREATMENT OF SMALL CELL LUNG-CANCER WITH VP-16, VINCRISTINE, DOXORUBICIN (ADRIAMYCIN), CYCLOPHOSPHAMIDE (EVAC), AND HIGH-DOSE CHEST RADIOTHERAPY [J].
GOODMAN, GE ;
MILLER, TP ;
MANNING, MM ;
DAVIS, SL ;
MCMAHON, LJ .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (08) :483-488
[13]  
GOODWIN JW, 1987, CANCER TREAT REP, V71, P99
[14]   TREATMENT OF ADVANCED-STAGE COLORECTAL ADENOCARCINOMA WITH FLUOROURACIL AND HIGH-DOSE LEUCOVORIN CALCIUM - A PILOT-STUDY [J].
HINES, JD ;
ZAKEM, MH ;
ADELSTEIN, DJ ;
RUSTUM, YM .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (01) :142-146
[15]  
IHDE DC, 1981, CANCER TREAT REP, V65, P755
[16]   PHASE-I STUDY OF SPIROGERMANIUM GIVEN DAILY [J].
LEGHA, SS ;
AJANI, JA ;
BODEY, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (05) :331-336
[17]   REDUCTION OF DOXORUBICIN CARDIOTOXICITY BY PROLONGED CONTINUOUS INTRAVENOUS-INFUSION [J].
LEGHA, SS ;
BENJAMIN, RS ;
MACKAY, B ;
EWER, M ;
WALLACE, S ;
VALDIVIESO, M ;
RASMUSSEN, SL ;
BLUMENSCHEIN, GR ;
FREIREICH, EJ .
ANNALS OF INTERNAL MEDICINE, 1982, 96 (02) :133-139
[18]  
MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO
[19]  
2-6
[20]   PHASE-1 CLINICAL-TRIAL OF A 3-DAY DIVIDED DOSE SCHEDULE OF IFOSFAMIDE (NSC109724) [J].
NELSON, RL ;
CREAVEN, PJ ;
COHEN, MH ;
FOSSIECK, BE .
EUROPEAN JOURNAL OF CANCER, 1976, 12 (03) :195-198